Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement

Size: px
Start display at page:

Download "Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement"

Transcription

1 Birmingham, Sandwell and Solihull Cardiac and Stroke Network Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Introduction This guidance informs prescribers and commissioners regarding the implementation of NICE TAG 256 on Rivaroxaban for prevention of stroke and systemic embolism in AF within Birmingham, Sandwell and Solihull. It sets out the network position on: A. The on-going place of warfarin in therapy. B. The areas for special consideration in relation to the use of rivaroxaban C. The management of specific patient groups D. Who should initiate rivaroxaban. Specifically that it should only be initiated by clinicians who routinely initiate warfarin. It does not seek to compare dabigatran with rivaroxaban. However, the Network notes that due to the difference in baseline risk between the study populations in RE-LY and ROCKET-AF, comparison of the two drugs is a complex issue. Recommendations NICE TA 256 Atrial fibrillation Rivaroxaban states: The decision about whether to start treatment with rivaroxaban should be made after an informed discussion between the clinician and the person about the risks and benefits of rivaroxaban compared with warfarin. For people who are taking warfarin, the potential risks and benefits of switching to rivaroxaban should be considered in light of their level of international normalised ratio (INR) control A. The Birmingham, Sandwell and Solihull Cardiac and Stroke Network considers that warfarin remains a valuable treatment option in the management of Atrial Fibrillation 1. Warfarin is an effective therapy for stroke prevention in atrial fibrillation with long term safety and efficacy data derived from multiple trials and from real world experience. 2. Continuous monitoring of warfarin can be an aid to patient adherence and education with regular opportunities to assess safety issues when a patients clinical situation changes. 3. Warfarin s known efficacy for secondary prophylaxis in patients with arterial vascular disease (equivalent to an antiplatelet drug). 4. Warfarin can be used in patients with renal impairment. 5. Warfarin has well established protocols for reversal of anticoagulation with Vitamin K and Prothrombin Complex Concentrate.

2 B. The Birmingham, Sandwell and Solihull Cardiac and Stroke Network recognises the published clinical data on the use of rivaroxaban in prevention of stroke and systemic embolism, but notes the following concerns in relation to its use: 1. The methodology of the ROCKET-AF trial was complex, with data from different populations within the study used to calculate non-inferiority and superiority for the primary efficacy endpoint. The study was designed and powered to test the hypothesis that rivaroxaban would be non-inferior to warfarin for the prevention of stroke and systemic embolism in the per-protocol as-treated population. This was demonstrated. The study methodology then allowed for testing for superiority in the safety population - this demonstrated superiority for rivaroxaban over warfarin for the same endpoint. However, in the intention to treat population (ie including data from all patients from randomisation through to the end of the study), superiority of rivaroxaban over warfarin was not demonstrated. The ITT population is usually considered to be that which provides the most helpful information to the clinician, representing as it does the entire period from the decision to prescribe through to the end of follow up, including any period after discontinuation of the medication. 2. As a new medicine, there is a lack of long-term clinical safety data. Clinicians should be aware that due to the design of the ROCKET-AF study, the safety data pertains to patients who received at least one dose of the study drug, and were followed for events whilst they were receiving the assigned study drug or within two days of discontinuation. Unlike many trials, the safety data reported therefore does not include any longer term safety data, including possible effects emerging following discontinuation. 3. Plasma concentration is related to renal function. A reduced dose is recommended in patients with CrCl 15-49ml/min. 4. There is currently no specific antidote antagonising the effect of rivaroxaban. The SmPC states that if symptomatic treatment of excessive bleeding is inadequate, administration of a specific procoagulant reversal agent should be considered however, this is based on limited non-clinical studies and there is very limited clinical experience with the use of products such as PCC,APcc and r-fviia 5. Rivaroxaban must be taken with food. 6. As there is currently no data on the pharmacokinetic implications of crushing tablets, either for direct administration, or in the production of special liquid formulations, BSSCSN considers that rivaroxaban cannot be recommended for individuals who are unable to swallow the tablet. C. The Birmingham, Sandwell and Solihull Cardiac and Stroke Network has considered the position of rivaroxaban and warfarin in each of the groups outlined below: 1. Patients for whom there are stronger indications for consideration of rivaroxaban as an alternative to warfarin for atrial fibrillation. 2. Patients who request rivaroxaban as their preferred choice in terms of a favourable lifestyle in comparison to warfarin (e.g. in terms of dietary restrictions and inconvenience of INR monitoring). 3. Patients with a new diagnosis of atrial fibrillation.

3 The following guidance is provided for clinicians within the BSSCSN in relation to each of these groups: 1. Patients for whom there are stronger indications for consideration of rivaroxaban as an alternative to warfarin for atrial fibrillation. The criteria below are a summary of suggestions by the steering committee of the West Midlands Thrombosis Forum as the strongest indications for consideration of rivaroxaban as an alternative to warfarin for atrial fibrillation. Allergic reaction/intolerance of coumarins (warfarin, phenindione, sinthrome) Patients with important and unavoidable drug interactions that favour rivaroxaban over warfarin e.g. chemotherapy in a patient at high risk of CVA where a clinician does not want to stop anticoagulation Patients in whom monitoring and/or coping with variable dose regimen is difficult but who are able to comply with a fixed dose drug regime. Previous significant bleed on warfarin in patients at high risk for stroke, if the bleed was associated with poor INR control in a patient who is believed to be adherent with prescribed medication. It should be noted that in the ROCKET-AF trial, Rivaroxaban was associated with a lower risk of intracranial bleeding than warfarin (approx 5 events per 1000 patients per year with rivaroxaban and approx 7 events per 1000 patient per year with warfarin), NNT = 500 Rivaroxaban was associated with a higher risk of major gastrointestinal bleeding than warfarin (approx 32 events per 1000 patient per year with rivaroxaban compared with approx 22 events per 1000 patient per year with warfarin), NNH = 100 Please note also that people with a condition which increased bleeding risk were excluded from the trial. Poor INR control (e.g. more than 2 INRs >8.0 or more than 3 INRs >5.0 in 6 months) Selection of patients based on time in treatment range (TTR) is complex. For patients with reduced TTR, a careful assessment of the contributory factors is essential. There is independent evidence that a TTR<40% could lead to an outcome worse than not being on warfarin at all. However, a lower TTR may indicate poor adherence with taking medications and therefore rivaroxaban would be unlikely to be advantageous in this situation. 2. Patients who request rivaroxaban as their preferred choice in terms of a favourable lifestyle in comparison to warfarin (e.g. in terms of dietary restrictions and inconvenience of INR monitoring). The BSSCSN Patient Clinician Discussion Guide, or the NICE Patient Decision Aid should be used to discuss the clinical benefits and risks. Absolute risk increases/decreases should be used wherever possible to allow the patient to set the risk in context (see Patient Clinician Discussion Guide). The concerns outlined in section B (above) should be carefully explored with the patient. Please see FAQs (Appendix 1) for further information on legal status of NICE guidance.

4 3. Patients with a new diagnosis of Atrial Fibrillation Patients awaiting cardioversion: This cohort of patients was excluded from ROCKET-AF, and no other clinical data is available. BSSCSN therefore cannot recommend the use of rivaroxaban in this patient group. Warfarin remains a reasonable option prior to cardioversion. For all other patients the BSSCSN Patient Clinician Discussion Guide, or the NICE Patient Decision Aid, should be used to discuss the clinical benefits and risks. Timing of discussions Other than in exceptional circumstances, it is not necessary for clinicians to actively seek out patients for consideration of rivaroxaban. For patients meeting the criteria in section C part 1, clinicians should consider initiating a discussion regarding rivaroxaban at the next routine appointment. Patients in group 2 will self-present. Discussion with patients in group 3 will be integral to the overall management planning. D. Network position on Initiation The Birmingham, Sandwell and Solihull Cardiac and Stroke Network recommends that discussions of the risks and benefits of rivaroxaban in comparison with warfarin should be undertaken by clinicians who routinely initiate warfarin. In many cases this will necessitate referral to the anti-coagulation service. The first prescription for rivaroxaban must be provided by the service initiating the medication. Prescribing may then be transferred to the patient s GP with a standardised clinical letter containing the following information Confirmation that the patient meets the NICE criteria Confirmation that an informed discussion the benefits and risks of rivaroxaban compared with warfarin has taken place Monitoring requirements Criteria for discontinuation

5 APPENDIX 1 Rivaroxaban FAQs Does this position statement refer to all use of rivaroxaban? No it refers only to the use of rivaroxaban in AF in accordance with NICE TAG 256, which states Rivaroxaban is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as: congestive heart failure hypertension age 75 years or older diabetes mellitus, prior stroke or transient ischaemic attack. Separate NICE guidance is available regarding use of rivaroxaban for prevention of VTE in patients following THR or TKR (TA157), and for the treatment of DVT and prevention of recurrent VTE and PE (TA261). Other potential indications are currently off-label, and have not been considered by NICE or local Formulary committees. Rivaroxaban is therefore not currently recommended for use in these indications, other than via exceptional circumstances processes. What is the legal position regarding a NICE TAG? Commissioners are legally required to provide funding for the provision of NICE approved medicines within 3 months of the publication date of the TAG. There is no legal requirement on the prescriber to prescribe it in all circumstances, and the TAG does not override the decision making or clinical responsibility of the prescriber for any individual patient, nor does it over-ride usual medico-legal principles. Does the NICE TAG mean that clinicians have to prescribe rivaroxaban for all patients who ask for it? No. The TAG clearly states that rivaroxaban is recommended as an option (see above) It goes on to state: The decision about whether to start treatment with rivaroxaban should be made after an informed discussion between the clinician and the person about the risks and benefits of rivaroxaban compared with warfarin. For people who are taking warfarin, the potential risks and benefits of switching to rivaroxaban should be considered in light of their level of international normalised ratio (INR) control This implies that the decision should be shared by the patient and the clinician, and not dominated by either party. Supporting the patient in understanding the benefits and risks of both warfarin and rivaroxaban, by presenting them in a way which puts them into a meaningful context will be an important part of the discussion. The NICE +/- BSSCSN resources for discussing risks and benefits are commended for this purpose. What about the NHS Constitution? The NHS Constitution states: You have a right to the drugs and treatments that have been recommended by NICE for use in the NHS, if your doctor says they are clinically appropriate for you. Please note in this TAG the recommendation is that rivaroxaban is an option.

6 Rivaroxaban checklist Item Indication Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age >75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Contraindications: Patients with creatinine clearance <15 ml/min; clinically significant active bleeding; hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C; pregnancy and breast feeding; patients receiving azole-antifungals (e.g. ketoconazole, itraconazole, voriconazole, posaconazole) or HIV protease inhibitors; patients receiving dronedarone (lack of data); hypersensitivity to the active substance or to any of the excipients. Cautions: Increased bleeding risk; concomitant use of other anticoagulants; creatinine clearance <30ml/min; strong CYP 3A4 inducers (e.g. rifampicin); NSAIDS; antiplatelet drugs. Discussed Benefits/risks Rivaroxaban i compared with dose-adjusted warfarin. Stroke/systemic embolism No benefit for either rivaroxaban or warfarin (difference not statistically significant) Major bleeding No benefit for either rivaroxaban or warfarin (difference not statistically significant) Intracranial bleeding Favours rivaroxaban 2 fewer events per 1,000 patients per year Gastrointestinal (upper,lower and rectal) bleeding Favours warfarin 10 fewer events per 1,000 patients per year Mortality No benefit for either rivaroxaban or warfarin (difference not statistically significant) Summary Rivaroxabani is about as good as warfarin in preventing stroke and blood clots, and has a similar risk of major bleeding. Side effects/tolerability Overall No benefit for either rivaroxaban or warfarin (difference not statistically significant) Epistaxis Favours warfarin (10.1% rivaroxaban vs 8.6% warfarin) Study withdrawal Comparable with both rivaroxaban and warfarin (23.7% rivaroxaban vs 22.2% warfarin)

7 Item Monitoring and convenience Warfarin - Frequency of blood tests/ dose adjustments Rivaroxaban may require initial renal function test to determine dose Routine health checks required in case of unexplained bleeding Drug interactions Discussed Dosing and administration Warfarin not suitable for dosette boxes (due to variable dose) Rivaroxaban may not be suitable for people with swallowing difficulties as no data available on crushing tablets Antidotes There may be a need to reverse anticoagulation if Serious bleeding following a fall or accident, Serious bleeding without external cause Urgent requirement for surgery INR (warfarin) too high due to dietary change, drug interaction Vit K / PCC for warfarin There is no specific antidote to rivaroxaban. Consideration may be given to use of procoagulant products such as PCC, but this recommendation is largely based on limited non-clinical data as there is very limited clinical data relating to use. Areas of uncertainty Limited patient exposure and lack of long-term safety data for rivaroxaban End Note i Rivaroxaban 20mg o.d., or 15mg o.d. in patients with creatinine clearance of 30 to 49ml per minute (ROCKET-AF population)

8 Rivaroxaban Patient Clinician Discussion Guide What did NICE say 1? Rivaroxaban is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as: congestive heart failure hypertension age 75 years or older diabetes mellitus, prior stroke or transient ischaemic attack. The decision about whether to start treatment with rivaroxaban should be made after an informed discussion between the clinician and the person about the risks and benefits of rivaroxaban compared with warfarin. For people who are taking warfarin, the potential risks and benefits of switching to rivaroxaban should be considered in light of their level of international normalised ratio (INR) control Does this mean my doctor has to prescribe it for me if I want it? Some people cannot take rivaroxaban because of other health conditions. In this case, their doctor would not prescribe it for them, even if they met the NICE criteria above. You should not take rivaroxaban if: You have an allergy to rivaroxaban or a component of the tablet You have extremely poor kidney function You have another illness causing significant bleeding You have liver disease associated with clotting problems and bleeding risk You need to take ketoconazole or similar drugs, dronedarone or HIV medication, You are pregnant or breast-feeding. If you have an increased risk of bleeding, your doctor will need to consider the risks of rivaroxaban particularly carefully. Some people take warfarin for conditions other than to reduce the risk of stroke due to atrial fibrillation. This NICE guidance does not apply to those conditions. If you meet the NICE criteria, then you and your doctor (or nurse or pharmacist) should have a discussion about whether rivaroxaban or warfarin is better for you. This means thinking about the possible benefits, and possible problems, associated with taking rivaroxaban compared with warfarin. This guide is to help you and your doctor to go through what we know about the positives and negatives about rivaroxaban, compared with warfarin, and to highlight some of the things that we don t know about it yet. End Note 1 If you do not meet at least one of the criteria in the NICE guidance then you would only be considered for rivaroxaban in exceptional circumstances.

9 What do I need to consider? Important information about clinical trials, benefits and harms Every medicine has good points (benefits) and bad points (harms, or side effects ). These are worked out on a large scale by doing trials of the medicine in lots of people, so we can get an idea of how many people will get the benefit, and how many will experience a side effect. The big trial that compared rivaroxaban with warfarin in patients with atrial fibrillation was called ROCKET-AF. Of course, not everyone will actually get a benefit many people would not have had a bad event like a stroke whether they took the medicine or not - and sadly some people will still have the bad event even if they do take the medicine. However, out of all the people who take the medicine, a small number of people will be prevented from having the bad event. Similarly, most people will not suffer harm, such as dangerous bleeding, from taking the medicine. A small number of people would have suffered harm whether they took the medicine or not. However, out of all the people who take a medicine, a small number of people will suffer harm who would not have done if they had not taken that medicine. We can t tell beforehand which person will fall into which category, so we can t tell you specifically whether you will be someone for whom taking rivaroxaban (rather than warfarin) prevents a bad event, someone in whom it causes a dangerous or unpleasant side effect, or someone in whom it has neither a positive nor a negative effect. It s important to note that some people were not allowed to take part in the study e.g. if they had just had a stroke or mini-stroke, if they were at high risk of bleeding, or had severe kidney or liver problems, a severe heartvalve disorder, uncontrolled hypertension or were pregnant. People for whom cardioversion was planned were also excluded from the trial. If you have one of these conditions, then either rivaroxaban may not be suitable for you, or the balance of benefits and risks may be different. The information from clinical trials involves thinking about some numbers, so everything in this section is presented in terms of considering benefits and harms/side effects per 1,000 people treated for one year.

10 What did the ROCKET-AF trial show? Efficacy and safety Looking at the numbers of people who had a stroke or a blood clot: There was no difference 2 in the risk of having a stroke or blood clot with rivaroxaban compared with warfarin Looking at the numbers of people who had major bleeding: There was no difference 2 in the risk of having a major bleed with rivaroxaban compared with warfarin Looking at the people who had bleeding in the brain For every 1,000 people treated for one year Number of bleeds in the brain with rivaroxaban 5 Number of bleeds in the brain with warfarin 7 Number of bleeds in the brain prevented by using rivaroxaban 2 per 1,000 people Risk of dying Overall, the risk of dying was the same for people taking rivaroxaban as people taking warfarin. In summary - Rivaroxaban is about as good as warfarin in preventing stroke and blood clots, and has a similar risk of major bleeding. Side effects and tolerability The rate of most side effects was the same whether people were taking rivaroxaban or warfarin. However, more people experienced epistaxis (nose-bleed) with rivaroxaban than with warfarin For every 1,000 people (rounded figures) Epistaxis (nose-bleed) with rivaroxaban 101 Epistaxis (nose-bleed) with warfarin 86 Additional cases of epistaxis (nose-bleed) with rivaroxaban 15 per 1,000 people End Note 2 no difference is used to indicate that the difference in the point estimates was not statistically significant

11 Overall, about the same number of people stopped taking the medicine and withdrew from the study with rivaroxaban as did with warfarin. So what else might I need to think about? Monitoring and convenience Unlike warfarin, rivaroxaban does not need regular blood tests and dose adjustments, and there are no special dietary requirements. There are fewer drug interactions. A person who is considering rivaroxaban may be asked to have a test before starting it to check how well their kidneys are working. Any person taking a blood thinning medicine should have regular health checks in case of unexplained bleeding. Remembering to take the medicine Warfarin is taken once a day. It is not suitable for dosette boxes and similar systems, as there may be a need to change the dose. Rivaroxaban is also taken once a day. It is important to be confident that you will be able to remember to do this, especially as there is no monitoring to give you regular feedback on your blood levels. We do not have any information on whether it is safe to crush tablets, so rivaroxaban may not be suitable for people with swallowing difficulties. Antidote Sometimes there may be a need to reverse the blood-thinning (anticoagulation) effect e.g. INR (warfarin) too high due to dietary change, drug interaction Blood level ( rivaroxaban) too high e.g. due to gradual or sudden reduction in kidney function. Serious bleeding following a fall or accident, Serious bleeding without external cause Urgent requirement for surgery The effect of warfarin can be reversed using a Vitamin K antidote, and various blood products can be used to help to reduce or stop bleeding. There is currently no known antidote to rivaroxaban, so there are few options for controlling excessive bleeding. Certain treatments might reduce bleeding, but there is limited clinical experience with this. Some areas of uncertainty Because warfarin has been used for many years, the side effects are well known, and doctors and nurses are familiar with dealing with them. Rivaroxaban is a very new drug, so we know much less about it than we do about warfarin. It is not uncommon for more information about side effects to become apparent once more people start using a medicine outside the carefully controlled circumstances of a clinical trial. Sometimes these may not emerge until after several years of use, and sometimes they may be serious. It may be helpful to be aware that in the past ten years there have been examples of new drugs where no serious concerns have emerged, and others where concerns have been so great that the drug has been withdrawn for safety reasons. At this stage it is not possible to tell what the future holds for rivaroxaban.

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /

More information

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications

More information

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions What is atrial fibrillation?...2 What are dabigatran, rivaroxaban and apixaban and what are they used for?...2

More information

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1

More information

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as

More information

The Role of the Newer Anticoagulants

The Role of the Newer Anticoagulants The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention

More information

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

VOLUME No: 21 04 written by Sara Wilds & Kathryn Buchanan. Date of issue: June 2012 (updated November 2012 following NICE TA 256)

VOLUME No: 21 04 written by Sara Wilds & Kathryn Buchanan. Date of issue: June 2012 (updated November 2012 following NICE TA 256) Prescribing Points A NEWSLETTER FOR ALL HEALTH CARE PROFESSIONALS IN OXFORDSHIRE, WRITTEN BY THE MEDICINES MANAGEMENT TEAM, OXFORDSHIRE PCT, JUBILEE HOUSE, OXFORD BUSINESS PARK SOUTH, OXFORD, OX4 2LH.

More information

Patient frequently asked questions

Patient frequently asked questions Patient frequently asked questions What is atrial fibrillation?...2 What are dabigatran and rivaroxaban and what are they used for?...2 Which is better, dabigatran or rivaroxaban?...2 For patients with

More information

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban

More information

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Appendix C Factors to consider when choosing between anticoagulant options and FAQs Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened

More information

Dorset Cardiac Centre

Dorset Cardiac Centre P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February

More information

TSOAC Initiation Checklist

TSOAC Initiation Checklist Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.

More information

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 22-23 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke

More information

XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING

XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING XARELTO (RIVAROXABAN) EDUCATIONAL PACK FOR 15MG AND 20MG DOSING NOW UPDATED A N D I N C L U D E S A NEW INDICATION Prevention of stroke and systemic embolism in eligible adult patients with non-valvular

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

Novel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers

Novel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers Novel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers How does it work? Dose and Administration Monitoring Warfarin Dabigatran Rivaroxaban Apixaban Warfarin has an

More information

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation

More information

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance

More information

FDA Approved Oral Anticoagulants

FDA Approved Oral Anticoagulants FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic

More information

Bios 6648: Design & conduct of clinical research

Bios 6648: Design & conduct of clinical research Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment

More information

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction

More information

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE

XARELTO (RIVAROXABAN) PRESCRIBER GUIDE XARELTO (RIVAROXABAN) PRESCRIBER GUIDE Prescribing information found on pages 16-17 This guide is to be used to support the appropriate use of Xarelto in the following indications: Prevention of stroke

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions

More information

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:

More information

Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists

Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Traffic light classification- Amber 2 specialist initiation Information sheet for Primary Care Prescribers

More information

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Issued: May 2012 guidance.nice.org.uk/ta256 NICE has accredited the process used by the Centre for Health

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

NOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions

NOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions AC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions FAQ document jointly prepared by NHSGGC Haematology Service & Medicines Infmation On behalf of the Heart MCN

More information

PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline

PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline The aim of this document to guide clinicians on use of novel anticoagulants for stroke

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

Volume 7; Number 19 November 2013

Volume 7; Number 19 November 2013 Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire

More information

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016

More information

Atrial fibrillation (non-valvular) and reducing the risk of a stroke Management Options Brief Decision Aid

Atrial fibrillation (non-valvular) and reducing the risk of a stroke Management Options Brief Decision Aid Atrial fibrillation (non-valvular) and reducing the risk of a stroke Management Options Brief Decision Aid Atrial fibrillation (AF) increases your risk of having a stroke (a blood clot in the brain). From

More information

Service Specification Template Department of Health, updated June 2015

Service Specification Template Department of Health, updated June 2015 Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.

More information

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012 New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk

More information

NORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION

NORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial

More information

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,

More information

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide Simple Protection For More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation 4 Patients

More information

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has

More information

Implementation of NICE TAs 261 and 287

Implementation of NICE TAs 261 and 287 Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group Northampton General Hospital NHS Trust Northamptonshire Healthcare Foundation Trust Implementation

More information

Anticoagulant therapy

Anticoagulant therapy Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in

More information

Xarelto (rivaroxaban) Prescriber Guide November 2012

Xarelto (rivaroxaban) Prescriber Guide November 2012 Xarelto (rivaroxaban) Prescriber Guide November 2012 Simple Protection for More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation

More information

Traditional anticoagulants

Traditional anticoagulants TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University

More information

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart

More information

Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options?

Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About

More information

Xarelto (Rivaroxaban)

Xarelto (Rivaroxaban) Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,

More information

Executive Summary. Motive for the request for advice

Executive Summary. Motive for the request for advice Executive Summary Motive for the request for advice Currently nearly 400,000 people in the Netherlands are being treated with anticoagulants of a type Vitamin K antagonists (VKAs). Although VKAs are very

More information

Atrial Fibrillation and Anticoagulants

Atrial Fibrillation and Anticoagulants York Teaching Hospital NHS Foundation Trust Atrial Fibrillation and Anticoagulants A guide to your diagnosis and treatment Information for patients, relatives and carers For more information, please contact:

More information

Objectives of Session

Objectives of Session Objectives of Session Project Background Why the need Decision Support Tool summary of key evidence Promotion Key Messages Project Background Grasp AF Audit Initial Grasp AF project undertaken in NHS Buckinghamshire

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide May 2013 Simple Protection for More Patients 2 Xarelto Prescriber Guide Patient Alert Card 4 Dosing Recommendations 4 Dosing in patients with atrial fibrillation

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT)

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015 Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents

More information

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NHS Evidence has accredited the process used

More information

Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)

Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing) Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Xarelto (rivaroxaban) Prescriber Guide

Xarelto (rivaroxaban) Prescriber Guide Xarelto (rivaroxaban) Prescriber Guide Patient Alert Card A patient alert card must be provided to each patient who is prescribed Xarelto 15 or 20 mg, and the implications of anticoagulant treatment should

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) Indication: Stroke Prevention in Atrial Fibrillation This recommendation supersedes the Canadian Drug Expert Committee (CDEC) recommendation for

More information

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead

More information

NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues

NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues Andy Hutchinson Medicines Education Technical Adviser NICE Medicines and Prescribing Centre Note: this is

More information

Comparison between New Oral Anticoagulants and Warfarin

Comparison between New Oral Anticoagulants and Warfarin Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several

More information

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.

More information

Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준

Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Contents Converting to/from rivaroxaban Measuring levels of rivaroxaban Patients potentially at higher risk of bleeding Renal

More information

Dabigatran in Atrial Fibrillation Question and Answers document to inform commissioners

Dabigatran in Atrial Fibrillation Question and Answers document to inform commissioners Dabigatran in Atrial Fibrillation Question and Answers document to inform commissioners West Midlands Commissioning Support Unit, Birmingham University /New Medicines Evaluation Unit, Keele University

More information

Prevention of stroke in patients with atrial fibrillation

Prevention of stroke in patients with atrial fibrillation www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent Primary Care Center

PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent Primary Care Center Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent

More information

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78

More information

East Kent Prescribing Group

East Kent Prescribing Group East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor

22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart

More information

Breadth of indications matters One drug for multiple indications

Breadth of indications matters One drug for multiple indications Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Atrial Fibrillation, Stroke Prevention Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be

More information

Version 8, 25 April 2013

Version 8, 25 April 2013 Hertfordshire Implementation of NICE TAs 249, 256 and 275 Apixaban, dabigatran and rivaroxaban, novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial

More information

GRASP-AF Coming to a PCT near you.

GRASP-AF Coming to a PCT near you. GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation

More information

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach. Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight

More information

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Updates to the Alberta Drug Benefit List. Effective January 1, 2016 Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

Volume 7; Number 15 August 2013

Volume 7; Number 15 August 2013 Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire

More information

COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.

COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals. COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new

More information

Rivaroxaban (Xarelto) in the management of stroke and DVT

Rivaroxaban (Xarelto) in the management of stroke and DVT Rivaroxaban (Xarelto) in the management of stroke and DVT Steve Chaplin MSc, MRPharmS, Victoria Haunton BM, DGM, MRCP, Thompson Robinson BMedSci, MD, FRCP and Catherine Bagot MD, FRCPath KEY POINTS is

More information

Title of Guideline. Thrombosis Pharmacist)

Title of Guideline. Thrombosis Pharmacist) Title of Guideline Contact Name and Job Title (author) Guideline for patients receiving Rivaroxaban (Xarelto ) requiring Emergency Surgery or treatment for Haemorrhage Julian Holmes (Haemostasis and Thrombosis

More information

An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban)

An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Sabiha Fatima Hussaini Sabiha.hussaini@salisbury.nhs.uk An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) April

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

3/3/2015. Patrick Cobb, MD, FACP March 2015

3/3/2015. Patrick Cobb, MD, FACP March 2015 Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict

More information

Dabigatran (Pradaxa) Guidelines

Dabigatran (Pradaxa) Guidelines Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without

More information